Vivaldi Biosciences Inc. Acquires Clinical-Stage Influenza Vaccine Assets
10/10/2013 9:59:05 AM
FORT COLLINS, Colo.--(BUSINESS WIRE)--Vivaldi Biosciences Inc. (Vivaldi), a biotechnology company developing live attenuated influenza vaccines (LAIVs) against pandemic and seasonal influenza, today announced that it has acquired from Baxter Healthcare SA (Glattpark, Switzerland) research and development assets, including intellectual property, clinical data, know-how and materials, for LAIVs in which the gene for influenza nonstructural protein 1 (NS1) has been fully deleted. These assets previously were owned by AVIR Green Hills Biotechnology AG (Vienna, Austria).
Help employers find you! Check out all the jobs and post your resume.
comments powered by